[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481056":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":21,"collaborators":7,"id":23,"slug":7,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":26,"acronym":7,"eligibilityCriteria":27,"healthyVolunteers":24,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":28,"phases":7,"briefSummary":29,"conditions":30,"keywords":32,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":39,"locationsCount":7},{"fullName":5,"class":6},"Incyte Corporation","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","axatilimab","Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks",[14],"INCA34176",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Incyte Corporation Medical Information Call Center (US)","CONTACT","1.855.463.3463","medinfo@incyte.com",{"type":22,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100481056",false,"NCT05544032","Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","This program is being offered on a patient by patient basis and will require company, Institutional Review Board\u002FIndependent Ethics Committee and Single Patient IND approval.",[31],"Chronic Graft Vs. Host Disease",[31,33],"cGVHD","AVAILABLE","2025-10-03",{"date":37,"type":38},"2025-10-08","ACTUAL",{"name":5,"class":6}]